1
IRUS TotalDownloads
The effect of TRV027 on coagulation in COVID 19: A pilot randomized, placebo-controlled controlled trial
File | Description | Size | Format | |
---|---|---|---|---|
![]() | Publication version | 1.11 MB | Adobe PDF | View/Open |
Title: | The effect of TRV027 on coagulation in COVID 19: A pilot randomized, placebo-controlled controlled trial |
Authors: | Robbins, AJ Che Bakri, NA Toke-Bjolgerud, E Edwards, A Vikraman, A Michalsky, C Fossler, M Lemm, N-M Medhipour, S Budd, W Gravani, A Hurley, L Kapil, V Jackson, A Lonsdale, D Latham, V Laffan, M Chapman, N Cooper, N Szydlo, R Boyle, J Pollock, KM Owen, D |
Item Type: | Journal Article |
Abstract: | COVID-19 causes significant thrombosis and coagulopathy, with elevated D-dimer a predictor of adverse outcome. The precise mechanism of this coagulopathy remains unclear, one hypothesis is that loss of Angiotensin Converting Enzyme 2 activity during viral endocytosis leads to pro-inflammatory angiotensin II accumulation, loss of angiotensin-1-7 and subsequent vascular endothelial activation. We undertook a double blind randomised, placebo controlled experimental medicine study to assess the effect of TRV027, a synthetic angiotensin-1-7 analogue on D-dimer in 30 patients admitted to hospital with COVID-19 (REC ref. 20/HRA/3414), Clinical Trial No. NCT04419610. The study showed a similar rate of adverse events in TRV027 and control groups. There was a numerical decrease in D-dimer in the TRV027 group and increase in D-dimer in the placebo group, however, this did not reach statistical significance (p=0.15). A Bayesian analysis demonstrated there was a 92% probability that this change represented a true drug effect. |
Issue Date: | Apr-2023 |
Date of Acceptance: | 18-Nov-2022 |
URI: | http://hdl.handle.net/10044/1/100559 |
DOI: | 10.1111/bcp.15618 |
ISSN: | 0306-5251 |
Publisher: | British Pharmacological Society |
Start Page: | 1495 |
End Page: | 1501 |
Journal / Book Title: | British Journal of Clinical Pharmacology |
Volume: | 89 |
Issue: | 4 |
Copyright Statement: | © 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
Publication Status: | Published |
Online Publication Date: | 2022-11-27 |
Appears in Collections: | Department of Immunology and Inflammation Department of Infectious Diseases National Heart and Lung Institute Faculty of Medicine Imperial College London COVID-19 Department of Brain Sciences |
This item is licensed under a Creative Commons License